Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AstraZeneca's ADC disappoints - on severe adverse events

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 01, 2024 2:10pm

103 Views

Post# 35909882

RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse events

The IRA mandates that certain small molecule drugs be subject to Medicare drug-pricing negotiations after nine years, while biologics can enjoy 13 years on the market before they’re up for price reductions.

AZ argued its Merck-partnered cancer drug Lynparza is one example of how the IRA's framework is flawed. Lynparza is a small molecule PARP inhibitor.

Today a federal court judge in Delaware ruled in favor of the IRA whereby biologics are given 13 years of market exclusivity in contrast to nine years for small molecules.

<< Previous

Bullboard Posts

Next >>

A PGM mining stock with value written all over it